The combined use of the drugs Gleevec and Sprycel may lower the chance of cancer relapse in chronic myeloid leukemia patients, a study reports. Both drugs, which target a protein that causes CML, may at least increase the length of time before the cancer recurs when used simultaneously instead of sequentially.

Full Story:

Related Summaries